Source: Eur Respir Rev 2017; 26: 160004
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Andrew M. Courtwright, Hilary J. Goldberg, Elizabeth Petri Henske, Souheil El-Chemaly. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. Eur Respir Rev 2017; 26: 160004

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of inhibitor mTOR in patients with lymphangioleiomyomatosis. Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 The therapeutic potential of a new phosphodiesterase inhibitor in acute respiratory distress syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 36s Year: 2002 ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012 Preventive and therapeutic effects of phosphoinositide 3-kinase inhibitors on acute lung injury Source: Annual Congress 2011 - Anti-inflammatory strategies in acute lung injury Year: 2011 Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020 JAK inhibitors overcome corticosteroid insensitivity in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Source: Eur Respir J 2003; 22: 20-27 Year: 2003 Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD) Source: ERS Lung Science Conference 2017 Year: 2017 The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Tyrosine kinase inhibition in pulmonary hypertension: the anti-proliferative approach Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017